 | • レポートコード：MRC2305C041 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界のリキッドバイオプシー市場規模が2021年に1,180.27百万ドル、2022年に1,417.69百万ドルとなり、更に年平均20.29％成長して2027年には3,576.17百万ドルに達すると予測しています。当市場調査レポートでは、リキッドバイオプシーの世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（無細胞DNA、循環腫瘍細胞、循環腫瘍DNA、エクソソーム、細胞外小胞）、サンプル別分析（血液ベース、尿ベース）、種類別分析（アッセイキット、器具、サービス）、用途別分析（早期がん検診、再発モニタリング、治療法選定、治療モニタリング）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書には、ANGLE PLC、Bio-Rad Laboratories, Inc.、Biocept, Inc.、Dxcover Limited、Epic Sciences、Exact Sciences Corporation、Exosome Diagnostics by Bio-Techne Corporation、F. Hoffmann-La Roche Ltd.、Foundation Medicine, Inc.、Freenome Holdings, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のリキッドバイオプシー市場規模：製品別 - 無細胞DNAの市場規模 - 循環腫瘍細胞の市場規模 - 循環腫瘍DNAの市場規模 - エクソソームの市場規模 - 細胞外小胞の市場規模 ・世界のリキッドバイオプシー市場規模：サンプル別 - 血液ベースリキッドバイオプシーの市場規模 - 尿ベースリキッドバイオプシーの市場規模 ・世界のリキッドバイオプシー市場規模：種類別 - アッセイキットの市場規模 - 器具の市場規模 - サービスの市場規模 ・世界のリキッドバイオプシー市場規模：用途別 - 早期がん検診における市場規模 - 再発モニタリングにおける市場規模 - 治療法選定における市場規模 - 治療モニタリングにおける市場規模 ・世界のリキッドバイオプシー市場規模：地域別 - 南北アメリカのリキッドバイオプシー市場規模 アメリカのリキッドバイオプシー市場規模 カナダのリキッドバイオプシー市場規模 ブラジルのリキッドバイオプシー市場規模 ... - アジア太平洋のリキッドバイオプシー市場規模 日本のリキッドバイオプシー市場規模 中国のリキッドバイオプシー市場規模 インドのリキッドバイオプシー市場規模 韓国のリキッドバイオプシー市場規模 台湾のリキッドバイオプシー市場規模 ... - ヨーロッパ/中東/アフリカのリキッドバイオプシー市場規模 イギリスのリキッドバイオプシー市場規模 ドイツのリキッドバイオプシー市場規模 フランスのリキッドバイオプシー市場規模 ロシアのリキッドバイオプシー市場規模 ... - その他地域のリキッドバイオプシー市場規模 ・競争状況 ・企業情報 |
The Global Liquid Biopsy Market size was estimated at USD 1,180.27 million in 2021 and expected to reach USD 1,417.69 million in 2022, and is projected to grow at a CAGR 20.29% to reach USD 3,576.17 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Liquid Biopsy to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, Exosome, and Extracellular Vesicles.
Based on Sample, the market was studied across Blood Based and Urine Based.
Based on Type, the market was studied across Assay Kits, Instruments, and Services.
Based on Technology, the market was studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.
Based on End User, the market was studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician’s Office Laboratories.
Based on Application, the market was studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
Based on Indication, the market was studied across Cancer Indication and Non-cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Liquid Biopsy market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Liquid Biopsy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Liquid Biopsy Market, including ANGLE PLC, Bio-Rad Laboratories, Inc., Biocept, Inc., Dxcover Limited, Epic Sciences, Exact Sciences Corporation, Exosome Diagnostics by Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc., Freenome Holdings, Inc., Guardant Health, Inc., Illumina, Inc., Inivata Limited, LungLife AI, Inc., Mdxhealth SA, Mesa Labs, Inc., Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., PerkinElmer, Inc., QIAGEN N.V., Strand Life Sciences Pvt. Ltd., Sysmex Corporation, and Thermo Fisher Scientific Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Liquid Biopsy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Liquid Biopsy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liquid Biopsy Market?
4. What is the competitive strategic window for opportunities in the Global Liquid Biopsy Market?
5. What are the technology trends and regulatory frameworks in the Global Liquid Biopsy Market?
6. What is the market share of the leading vendors in the Global Liquid Biopsy Market?
7. What modes and strategic moves are considered suitable for entering the Global Liquid Biopsy Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Incidence and Prevalence of Cancer
5.1.1.2. Increasing Preference for Noninvasive Diagnostic Procedures
5.1.1.3. Availability of Funding to Expand Cancer Research in the Field of Liquid Biopsy
5.1.2. Restraints
5.1.2.1. Low Abundance and Fragile Nature of the Circulating Tumor Cells (CTCs)
5.1.3. Opportunities
5.1.3.1. Significant use of Microarrays and Next-Generation Sequencing (NGS)
5.1.3.2. Ongoing Development of Advanced Liquid Biopsy Assays
5.1.4. Challenges
5.1.4.1. Unclear Regulatory and Reimbursement Scenario
5.2. Cumulative Impact of COVID-19
6. Liquid Biopsy Market, by Product
6.1. Introduction
6.2. Cell-free DNA
6.3. Circulating Tumor Cells
6.4. Circulating Tumor DNA
6.5. Exosome
6.6. Extracellular Vesicles
7. Liquid Biopsy Market, by Sample
7.1. Introduction
7.2. Blood Based
7.3. Urine Based
8. Liquid Biopsy Market, by Type
8.1. Introduction
8.2. Assay Kits
8.3. Instruments
8.4. Services
9. Liquid Biopsy Market, by Technology
9.1. Introduction
9.2. Multi-gene Parallel Analysis using NGS
9.3. Single-gene Analysis using PCR Microarrays
10. Liquid Biopsy Market, by End User
10.1. Introduction
10.2. Academic & Research Centers
10.3. Clinical Diagnostic Laboratories
10.4. Hospitals
10.5. Physician’s Office Laboratories
11. Liquid Biopsy Market, by Application
11.1. Introduction
11.2. Early Cancer Screening
11.3. Recurrence Monitoring
11.4. Therapy Selection
11.5. Treatment Monitoring
12. Liquid Biopsy Market, by Indication
12.1. Introduction
12.2. Cancer Indication
12.3.1. Breast Cancer
12.3.2. Colorectal Cancer
12.3.3. Lung Cancer
12.3.4. Melanoma
12.3.5. Prostate Cancer
12.3. Non-cancer Indication
13. Americas Liquid Biopsy Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Liquid Biopsy Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Liquid Biopsy Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. ANGLE PLC
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Bio-Rad Laboratories, Inc.
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. Biocept, Inc.
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Dxcover Limited
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Epic Sciences
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Exact Sciences Corporation
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. Exosome Diagnostics by Bio-Techne Corporation
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. F. Hoffmann-La Roche Ltd.
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. Foundation Medicine, Inc.
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. Freenome Holdings, Inc.
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. Guardant Health, Inc.
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Illumina, Inc.
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. Inivata Limited
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
17.14. LungLife AI, Inc.
17.14.1. Business Overview
17.14.2. Key Executives
17.14.3. Product & Services
17.15. Mdxhealth SA
17.15.1. Business Overview
17.15.2. Key Executives
17.15.3. Product & Services
17.16. Mesa Labs, Inc.
17.16.1. Business Overview
17.16.2. Key Executives
17.16.3. Product & Services
17.17. Myriad Genetics, Inc.
17.17.1. Business Overview
17.17.2. Key Executives
17.17.3. Product & Services
17.18. Natera, Inc.
17.18.1. Business Overview
17.18.2. Key Executives
17.18.3. Product & Services
17.19. Neogenomics, Inc.
17.19.1. Business Overview
17.19.2. Key Executives
17.19.3. Product & Services
17.20. PerkinElmer, Inc.
17.20.1. Business Overview
17.20.2. Key Executives
17.20.3. Product & Services
17.21. QIAGEN N.V.
17.21.1. Business Overview
17.21.2. Key Executives
17.21.3. Product & Services
17.22. Strand Life Sciences Pvt. Ltd.
17.22.1. Business Overview
17.22.2. Key Executives
17.22.3. Product & Services
17.23. Sysmex Corporation
17.23.1. Business Overview
17.23.2. Key Executives
17.23.3. Product & Services
17.24. Thermo Fisher Scientific Inc.
17.24.1. Business Overview
17.24.2. Key Executives
17.24.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing